CRSP

CRISPR Therapeutics AG - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR-based therapeutics. The company operates as a single segment and maintains a strategic collaboration with Vertex Pharmaceuticals for the development and commercialization of CASGEVY (exagamglogene autotemcel), the first approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Key Financial Metrics

Note: Revenue consists entirely of grant revenue ($865k). There was no collaboration revenue recognized in the period.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $19.4 million (16.6%) compared to Q1 2024, driven primarily by higher collaboration expenses and a decrease in other income.
• Collaboration Expenses: Collaboration expense, net, rose to $57.5 million from $47.0 million, an increase of $10.5 million. This was attributed to increased cost of goods sold and commercial costs related to CASGEVY and in vivo HSC editing.
• Operating Cash Flow: Net cash used in operating activities shifted from a positive $109.8 million in Q1 2024 to a negative $53.9 million in Q1 2025. This reversal was primarily due to the timing of receivable collections from Vertex ($200 million collected in Q1 2024 vs. $25 million in Q1 2025).
• Other Income: Other income, net, decreased by $11.2 million to $13.5 million, largely due to a change in the fair value of corporate equity securities and lower interest income.

Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($1.86 billion as of March 31, 2025) to fund operations and capital expenditures for at least the next 24 months.
• Clinical Updates: On May 6, 2025, the company announced initial top-line data for CTX310 (targeting ANGPTL3 for cardiovascular disease). The therapy demonstrated dose-dependent decreases in triglycerides and LDL, with reductions up to 82% in triglycerides and 81% in LDL-C in specific patient cohorts. No severe treatment-related adverse events were reported.
• Risk Factors: The filing highlights risks related to unfavorable global economic conditions, including new U.S. tariffs imposed on April 2, 2025, which could impact clinical trial operations and supply chains. Additionally, potential disruptions at the FDA and SEC due to government funding issues or staffing reductions pose risks to regulatory timelines.
• Capital Markets: The company utilized its At-The-Market (ATM) offering program in Q1 2025, selling 0.2 million shares for $8.7 million in proceeds. Approximately $354.8 million remains available under the current ATM prospectus.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $54 million quarterly operating cash burn against the $1.86 billion liquidity position.
• Vertex Receivables: Monitor the timing of future milestone or royalty payments from Vertex, as the Q1 2024 cash flow was significantly boosted by a $200 million collection that did not recur in Q1 2025.
• CTX310 Progression: Track the progression of the CTX310 Phase 1 trial following the positive initial data announcement to assess potential for future revenue streams.
• Collaboration Cost Structure: Review the trajectory of collaboration expenses with Vertex, which increased significantly in Q1 2025, to understand the impact on future profitability.
• Regulatory Environment: Assess the potential impact of U.S. government funding resolutions and FDA staffing levels on the approval timelines for CASGEVY and other pipeline candidates.